The FIP1-like-1 (FIP1L1)-platelet-derived growth factor receptoralpha (FIP1L1-PDGFR-a) fusion kinase causes hypereosinophilic syndrome (HES) in a defined subset of patients. Imatinib mesylate is a potent inhibitor of ABL but also of PDGFR-a, and has been associated with durable hematologic responses in patients with HES. However, development of mutations in the tyrosine kinase domain may hamper the activity of tyrosine kinase inhibitors (TKIs), which suggests that novel agents are warranted to prevent or overcome resistance. We evaluated the efficacy of the novel TKI EXEL-0862 in FIP1L1-PDGFR-aexpressing cell lines and in cells from a patient with HES harboring the FIP1L1-PDGFR-a gene. EXEL-0862 inhibited the proliferation of EOL-1 and imatinib-resistant T674I FIP1L1-PDGFR-a-expressing cells and resulted in potent inhibition of the phosphorylation of PDGFR-a and downstream proteins STAT3 and Erk1/2, both in vitro and ex vivo. Moreover, EXEL-0862 induced apoptotic death in EOL-1 cells and imatinibresistant T674I FIP1L1-PDGFR-a-expressing cells, and resulted in significant downregulation of the antiapoptotic protein Mcl-1 through a caspase-dependent mechanism. Our data establish EXEL-0862 as a solid candidate for the targeted treatment of patients with FIP1L1-PDGFR-a-positive HES.
Introduction
Hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterized by the presence of an absolute eosinophil count in peripheral blood equal or greater than 1.5 Â 10 9 /l for longer than 6 months in the absence of any recognized cause (e.g. parasitic infections, neoplastic disorders and collagen vascular diseases), and with evidence of target organ damage (e.g. heart, lung, skin) caused by eosinophilic tissue infiltration with release of cytoplasmic mediators. 1, 2 Historically, therapy for patients with HES has encompassed the use of corticosteroids or interferon-alpha. 3 A subset of patients with HES harbor the abnormal FIP1-like-1 (FIP1L1)-platelet-derived growth factor receptor-alpha (PDGFR-a) fusion gene, resulting from an 800 kb cryptic interstitial deletion involving chromosome 4q12. 4, 5 The discovery of this fusion gene has brought about not only taxonomic changes in the classification of eosinophilic chronic myeloproliferative disorders, but most importantly the development of new therapeutic approaches to HES. The presence of the FIP1L1-PDGFR-a fusion gene predicts response to the tyrosine kinase inhibitor (TKI) imatinib mesylate, 6 and patients with HES harboring this transcript generally respond to low (100 mg/day) imatinib doses. 4, 7 Occasional partial and complete responses to imatinib have been reported in patients with FIP1L1-PDGFR-anegative HES, 4, 8 suggesting genetic heterogeneity among patients with HES.
Despite its remarkable activity in chronic myelogenous leukemia (CML), therapy with imatinib has been challenged by the development of resistance associated with mutations in the Bcr-Abl kinase domain, which are encountered in 50-90% of patients with acquired imatinib resistance. [9] [10] [11] [12] This suggests that combinations of TKIs may be required for the maintenance of long-term responses in hematologic malignancies primarily treated with TKIs, such as CML or FIP1L1-PDGFR-a-expressing HES.
EXEL-0862, a novel TKI, has been optimized for activity against fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR) and FLT3. We recently reported that EXEL-0862 is a potent inhibitor of HMC-1.2 cells harboring the imatinib-resistant KIT D816V. 13 Since both KIT and PDGFRa belong to the receptor tyrosine kinase subclass III family and therefore bear structural similarities, we investigated the activity of EXEL-0862 against FIP1L1-PDGFR-a-bearing cells. We demonstrate that EXEL-0862 is a potent inhibitor of the activity of the FIP1L1-PDGFR-a fusion tyrosine kinase and of the phosphorylation of STAT3 and Erk1/2, leading to cell apoptosis. The apoptotic activity of EXEL-0862 appears to be ultimately mediated by downregulation of the antiapoptotic protein Mcl-1 through a caspase-3-dependent mechanism. Our data suggest EXEL-0862 holds promise as a candidate for the treatment of FIP1L1-PDGFR-a-positive HES and as a strategy to overcome and/or prevent clinical resistance to imatinib in patients with this disorder.
Materials and methods

Reagents and antibodies
EXEL-0862 (WO2004050681 A2) was provided from Exelixis, Inc. (South San Francisco, CA, USA) and stored as a 10 mM stock solution in dimethyl sulfoxide. Drug stock solutions were stored at À201C. Working dilutions were prepared in 10% media with freshly thawed aliquots for immediate use in experiments. z-DEVD-fmk (caspase-3 inhibitor), and z-VAD (pan-caspase inhibitor) were purchased from Sigma-Aldrich (St Louis, MO, USA) and z-VDVAD-fmk (caspase-2 inhibitor) from R&D Systems (Minneapolis, MN, USA). The MEK inhibitor CI1040 (PD184352, 2-(2-chloro-4-iodo-phenilamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide) was kindly provided by Dr JS Sebolt-Leopold (Cancer Molecular Sciences, Pfizer Global Research and Development, Ann Arbor, MI, USA). 14 Antibodies and their sources were as follows: antibodies against Mcl-1 (S-19) and protein-A/G agarose were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA); antibodies against poly(adenosine diphosphate (ADP)-ribose) polymerase (PARP) from Becton-Dickinson Biosciences Pharmingen (San Diego, CA, USA); rabbit polyclonal antibodies against caspase-3, caspase-9, XIAP, Bax and p-Erk1/2 and Erk1/2 were obtained from Cell Signaling Technology (Beverly, MA, USA); mouse monoclonal antibody specific against phosphotyrosine 705 of STAT3 (clone 9E12), rabbit polyclonal anti-Stat3, mouse monoclonal anti-phospho-STAT5A/B (Y694/Y699) (clone 8-5-2), anti-phosphotyrosine (4G10) and rabbit polyclonal anti-STAT5A and anti-PDGFR-a (07-276) were purchased from Upstate Technology (Lake Placid, NY, USA); mouse monoclonal antibody against actin from Sigma (St Louis, MO, USA); and anti-mouse immunoglobulin G and anti-rabbit immunoglobulin G horseradish peroxidase-conjugated antibodies were purchased from Amersham Biosciences (Arlington Heights, IL, USA).
Cell culture
The EOL-1 cell line was obtained from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany). This cell line contains the FIP1L1-PDGFR-a oncoprotein. 15 BaF3 cells expressing wild type (WT) or T674I FIP1L1-PDGFR-a were kindly provided by Dr Jan Cools.
4,7 MOLM13 was provided by Dr Andreeff M (The University of Texas MD Anderson Cancer Center). All cells lines were incubated in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (Hyclone, Logan, UT, USA), 1 unit/ml penicillin and 1 mg/ml streptomycin at 371C and 5% CO 2 .
Cell proliferation inhibition assay
The 3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (CellTiter 96Aqueous One Solution reagent, Promega Corporation, Madison, WI, USA) was used to evaluate the effect of EXEL-0862 on EOL-1 cell viability. The assay was done according to the manufacturer's recommendations. Briefly, 20000 EOL-1 cells per well were seeded in triplicate in 96-well microtiter plates (Falcon, Franklin Lakes, NJ, USA) and incubated in the presence of different EXEL-0862 concentrations for 72 h. EOL-1 cell proliferation was measured as a percentage of the proliferation of untreated cells. Four hours before culture termination, 20 ml of the MTS solution was added to the culture. During the incubation period, the MTS solution is reduced only by viable cells into an insoluble colored formazan. The absorbance/optical density was read on a 96-well plate reader at a single wavelength of 595 nm. The drug concentration resulting in 50% inhibition of cell proliferation (IC 50 ) was determined.
Cell cycle analysis by flow cytometry
After drug treatment, cells were collected, washed in Ca 2 þ -free phosphate-buffered saline (PBS) and fixed overnight in 70% cold ethanol at À201C. The cells were then washed twice in cold PBS and labeled with propidium iodide (PI) for 1 h in the dark. Cell cycle distribution, including the percentage of cells in sub-G1 phase, was determined using a FACScalibur flow cytometer equipped with CellQuest software (Becton Dickinson Systems, San Jose, CA, USA).
Measurement of mitochondrial transmembrane potential
Following treatment with EXEL-0862, changes in inner mitochondrial transmembrane potential (DC m ) in EOL-1 cells were examined by flow cytometry after incubation with submicromolar concentrations of MitoTracker probes. Briefly, cells were stained with two probes: MitoTracker Red (chloromethyl-Xrosamine [CMXRos]; Molecular Probes, Eugene, OR, USA) and MitoTracker Green FM (MTGreen; Molecular Probes). Cells were washed in Ca 2 þ -free PBS, stained with MitoTracker dyes and incubated at 371C for 1 h in the dark. MitoTracker probes passively diffuse across the plasma membrane and accumulate into the mitochondria. CMXRos is taken up by mitochondria as a result of the DC m and reacts with thiol residues to form covalent thiol ester bonds. MTGreen FM preferentially accumulates in mitochondria regardless of the mitochondrial membrane potential which makes it a useful tool for determining mitochondrial mass. MTGreen FM is a mitochondrion-selective probe that contains a thiol-reactive chloromethyl moiety and becomes fluorescent in the lipid environment of mitochondria. Samples were analyzed in a flow cytometer and analyzed using CellQuest software (Becton Dickinson).
Apoptosis assay by flow cytometry
To determine the proportion of apoptotic EOL-1 cells after incubation in the presence of EXEL-0862, cells were pelleted, washed in Ca 2 þ -free PBS and then resuspended in 100 ml of annexin V binding buffer (10 mM 4-[2-hydroxyethyl]-1-piperazineethane-sulfonic acid, (pH 7.4); 0.15 M NaCl; 5 mM KC1; 1 mM MgCl 2 ; 1.8 mM CaCl 2 ) before the fluorogenic substrate annexin V-fluoroisothiocyanate (Sigma-Aldrich) was added. Next, cells were incubated for 15 min at room temperature in the dark. After incubation, cells were washed in 2 ml Ca 2 þ -free PBS and resuspended in 0.5 ml of binding buffer. PI was added to permit identification and exclusion of cells that had lost membrane integrity during analysis. Binding of annexin V to apoptotic cells was determined by using a flow cytometer and the resulting data were analyzed using the CellQuest software. For the apoptosis analysis in BaF3 FIP1L1-PDGFRa-expressing cells, annexin V-fluoroisothiocyanate was replaced with annexin V conjugated with R-phycoerythrin (Annexin V-R-PE, Caltag, CA, USA).
Preparation of cell lysates, SDS-PAGE and immunoblotting Preparation of total cell lysates. Control cells and EOL-1 cells treated with EXEL-0862 were rinsed with PBS and then lysed with radioimmunoprecipitation assay (RIPA) buffer (1 Â PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS) supplemented with freshly added 10 mM b-glycerophosphate, 1 mM sodium orthovanadate, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, and 1 Â Roche complete Mini protease inhibitor cocktail (Roche, Indianapolis, IN, USA). The DNA in the lysates was sheared by rapidly passing the lysate 10 times through a 23-gauge needle.
Cytosolic fraction extraction. Control cells and cells treated with EXEL-0862 were washed twice with ice-cold PBS.
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Cell pellets were mildly resuspended with digitonin extraction buffer (10 mM PIPES (pH 6.8), 0.015% (w/v) digitonin, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl 2 , 5 mM ethylenediaminetetraacetic acid and 1 mM phenylmethylsulfonyl fluoride supplemented with freshly added phosphatase inhibitors and protease inhibitors as described in the preceding paragraph. After incubation on ice for 10 min, samples were centrifuged at 14 000 rpm for 10 min. Supernatants containing cytosolic protein were transferred to a clean tube. Protein concentration was determined in the final supernatant using the Bio-Rad protein assay dye reagent, following the manufacturer's instructions (Bio-Rad, Hercules, CA, USA). Samples were then stored in aliquots at À801C. Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and immunoblotting were described previously. 16 
Immunoprecipitation
Immunoprecipitation was carried out according to previously described methods. 17 In brief, total cell lysates obtained from control or treated cells were mixed with 3 mg of mouse antihuman PDGFR-a polyclonal antibody overnight at 41C, followed by the addition of 50 ml of protein-A/G agarose slurry, and incubated for 3 h. The immunoprecipitated complex was washed three times and then subjected to Western blotting.
Transmission electron microscopy
EOL-1 cells were treated with or without EXEL-0862 and then fixed with 2% glutaraldehyde plus 2% paraformaldehyde in 0.1 M cacodylate buffer (pH 7.3) for 1 h. After fixation, the samples were washed with 1% cacodylate-buffered tannic acid, postfixed with 1% buffered osmium tetraoxide for 1 h and stained en bloc with 1% uranyl acetate. The samples were dehydrated in ethanol and embedded in Spurr's low-viscosity medium. The samples were polymerized in an oven at 601C for 2 days. Ultrathin sections of the samples stained with uranyl acetate and lead citrate were examined under a JEM 1010 transmission electron microscope (JEOL USA Inc., Peabody, MA, USA) at an accelerating voltage of 80 kV. Apoptotic cells were observed at Â 5000 magnification, while details of the mitochondrial morphology were further observed at Â 50 000 magnification.
Patient sample
Peripheral blood was obtained from a 22-year-old male diagnosed with HES who presented with a white blood cell count of 16 Â 10 9 /l and a differential showing 71% eosinophils, 16% neutrophils, 12% lymphocytes and 1% basophils. Polymerase chain reaction analysis demonstrated the presence of FIP1L1-PDGFR-a transcript (data not shown). The research protocol was approved by the Institutional Review Board. Mononuclear cells were separated by Histopaque (density 1.077) gradient centrifugation and grown in RPMI 1640 supplemented with 20% serum overnight. Cells were then cultured in RPMI medium with 10% serum and subsequently exposed to 0.1 and 1.0 mM EXEL-0862 for 24 h before harvest. Cell lysates were prepared in RIPA buffer.
Statistical analysis
GraphPad Prism 4.0 software (GraphPad Software, San Diego, CA, USA) was used to perform the statistical analysis. A P-value of less than 0.05 was considered statistically significant.
Results
EXEL-0862 is a potent inhibitor of the proliferation of EOL-1 and T674I FIP1L1-PDGFR-a-expressing BaF3 cells
The EOL-1 cell line expresses in-frame FIP1L1-PDGFR-a fusion transcripts, with the fusion of exon 9 of FIP1L1 to a truncated exon 12 of PDGFR-a, 15 making it an ideal model for the in vitro study of HES. EXEL-0862 is a potent inhibitor of PDGFR with IC 50 of 2.1 nM and 1.1 nM for the a and b isoforms, respectively. 13 EOL-1 cells were treated with escalating doses of EXEL-0862 for 3 h. Cell lysates were immunoprecipitated with anti-PDGFR-a antibody and membranes were subsequently probed with the pan-anti-phosphotyrosine antibody 4G10. As shown in Figure 1a , untreated EOL-1 cells (control) showed Figure 1 EXEL-0862 inhibits PDGFR-a phosphorylation and proliferation of FIP1L1-PDGFR-a-expressing cells and peripheral blood mononuclear cells from a patient with HES carrying FIP1LI-PDGFR-a. (a) After exposure for 3 h to EXEL-0862, EOL-1 cells were harvested, cell lysates were immunoprecipitated with anti-PDGFR-a antibody, and membranes were probed with 4G10 (a pan-anti-phosphotyrosine antibody), anti-PDGFR-a and anti-phospho-PDGFR-a antibodies, respectively. (b) Mononuclear cells from a patient with HES were grown overnight in RPMI medium supplemented with 20% serum. Cells were then incubated in RPMI supplemented with 10% serum and exposed to EXEL-0862 at the indicated concentration for 24 h before harvest. Whole lysates in RIPA buffer were subjected to SDS-PAGE. Phosphorylation of PDGFR-a was examined as described in Figure 1a . (c and d) Exponentially growing EOL-1 cells (c) and BaF3 cells expressing WT or T674I FIP1L1-PDGFR-a (d) were exposed in vitro for 72 h to increasing concentrations of EXEL-0862 and the MTS assay was employed to evaluate growth inhibition. Graphs represent data from three independent experiments. EXEL-0862 inhibits FIP1L1-PDGFR-a-expressing cells J Pan et al appreciable levels of PDGFR-a phosphorylation, which is consistent with previously reported constitutive activation and autophosphorylation of the PDGFR-a fusion kinase in EOL-1 cells. 15 Exposure to EXEL-0862 resulted in dose-dependent inhibition of PDGFR-a phosphorylation in EOL-1 cells. When phosphotyrosine blots were re-probed with anti-PDGFR-a, PDGFR-a levels remained constant, indicating that EXEL-0862 abolishes phosphorylation without altering protein expression. Next, we replicated these experiments using peripheral blood mononuclear cells from one patient with HES. Cells were exposed to 0.1 and 1.0 mM, respectively for 24 h. As shown in Figure 1b , Western blotting showed that PDGFR-a phosphorylation was effectively inhibited by EXEL-0862 even at the lower concentration tested (0.1 mM).
In order to define the proliferation inhibitory activity of EXEL-0862 against human FIP1LI-PDGFR-a-expressing cells, we exposed exponentially growing EOL-1 cells in vitro to increasing concentrations of EXEL-0862 for 72 h. The MTS assay was used to evaluate cell viability. EXEL-0862 induced a dramatic inhibition in EOL-1 cell proliferation with an IC 50 of 1.0 nM (Figure 1c) . We next examined the activity of EXEL-0862 against BaF3 cells expressing FIP1LI-PDGFR-a. Notably, cells expressing the imatinib-resistant T674I mutant FIP1LI-PDGFR-a isoform were four times more sensitive to EXEL-0862 than those expressing WT FIP1LI-PDGFR-a ( Figure 1d and Table 1 ). As shown in Table 1 , EXEL-0862 was also a potent inhibitor of the proliferation of MOLM13 cells, which carry FLT3-ITD mutation, with an IC 50 of 14 nM. However, EXEL-0862 failed to inhibit the proliferation of K562 cells, which carry Bcr-Abl, with IC 50 values of 1-8 mM (data not shown). Additionally, HL-60 cells, which carry WT PDGFR-a, were rather resistant to EXEL-0862 with an IC 50 value of more than 5 mM (data not shown).
EXEL-0862 inhibits the activation of FIP1LI-PDGFR-a downstream targets STAT3 and Erk1/2
Since EXEL-0862 inhibited PDGFR-a phosphorylation, we reasoned that downstream signal-transduction events that are critical in promoting PDGFR-a-mediated cell survival might be also inhibited by EXEL-0862. To this end, EOL-1 cells were exposed to escalating concentrations of EXEL-0862 for 24 h. Phosphorylation of STAT3 and Erk1/2 was evaluated using their respective phospho-specific antibodies by Western blot. Baseline phosphorylation of STAT3 and Erk1/2 was detectable in untreated EOL-1 cells (Figure 2) . Upon exposure to EXEL-0862 at escalating concentrations, STAT3 phosphorylation was potently abrogated, even at doses as low as 2 nM. Inhibition of Erk1/2 phosphorylation was similar to that of STAT3 and was readily observed at the lowest EXEL-0862 concentration tested, thus suggesting that EXEL-0862 is a potent inhibitor of the MEK/ Erk pathway.
EXEL-0862 induces apoptosis in FIP1L1-PDGFR-aexpressing cells
We next analyzed the ability of EXEL-0862 to induce apoptosis in EOL-1 cells. Exposure of EOL-1 cells to escalating doses of EXEL-0862 for 24 h was followed by dose-dependent specific cleavage of PARP, which is a widely accepted marker of caspase activation and apoptosis. 18 Noteworthy, cleavage of PARP was paralleled by degradation of caspase-9 and caspase-3 (Figure 3a) . When analyzed by flow cytometry using annexin-V and PI staining, EOL-1 cells treated with EXEL-0862 showed dose-dependent apoptotic cell death (Figure 3b) . Analysis of EOL-1 cells by electron microscopy revealed typical morphologic features, characterized by homogeneous condensation of chromatin to one side or the periphery of the nuclei, confirming that EXEL-0862 induced cell death by apoptosis (Figure 3c (Figure 3d ). We also examined whether EXEL-0862 effectively induces apoptosis in BaF3 cells expressing WT or T674I FIP1L1-PDGFR-a. After exposure to 1 mM imatinib for 24 h, imatinib induced a significant increase in the percentage of apoptotic BaF3 cells expressing WT FIP1L1-PDGFR-a, but not in those expressing T674I FIP1L1-PDGFR-a (Figure 3e) , suggesting that the T674I mutation induces resistance to imatinib. In contrast, exposure to 1 mM EXEL-0862 induced significant apoptosis in BaF3 cells expressing either WT or T674I FIP1L1-PDGFR-a (Figure 3e) .
To examine whether EXEL-0862 induces disturbances in cell cycle, we exposed EOL-1 cells to EXEL-0862 for 24 h. Our results revealed that the number of sub-G1 apoptotic cells increased whereas the number of cells in different cell cycle phases was consistently decreased across the G 1 , S and G 2 phases after 24 h of treatment with 10 nM EXEL-0862 (Figure 3f ).
EXEL-0862 treatment leads to mitochondrial damage and cytochrome c release
To explore the mechanism of apoptosis induced by EXEL-0862 on EOL-1 cells, we measured the DC m and cytochrome c translocation from mitochondria to the cytoplasm, which have been correlated with induction of apoptotic cell death. EOL-1 cells were exposed to escalating EXEL-0862 concentrations for 24 h and the mitochondrial uptake of CMXRos and MTGreen double staining was measured by flow cytometry. A dosedependent decrease in DC m was observed (Figure 4a ). The level of cytochrome c in the cytosolic fraction was elevated at 16 h Table 1 Inhibitory concentrations of EXEL-0862 against different cell lines 
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after treatment (Figure 4b ). This was in agreement with the kinetics of other apoptotic indices, such as caspase activation and PARP cleavage. Next, we evaluated morphologic mitochondrial changes in EOL-1 cells undergoing EXEL-0862-induced apoptosis by transmission electron microscopy. Prominent ultrastructural changes, particularly related to condensation of the mitochondria, were observed 16 h after exposure to EXEL-0862 (Figure 4c ), which was concomitant with PARP cleavage and activation of caspase-3 and caspase-9 ( Figure 3c ). Occasionally, mitochondria of apoptotic EXEL-0862-treated EOL-1 cells exhibited an electron-dense matrix and lightly stained crestae.
To gain further insight into the mechanisms of EXEL-0862-induced apoptosis, we investigated whether EXEL-0862 causes WT and T674I FIP1L1-PDGFR-a-expressing BaF3 cells were exposed to 1 mM EXEL-0862 for 24 h before apoptosis assay by flow cytometry. (f) EXEL-0862 increased the sub-G1 and decreased the G1, S and G2 populations. EOL-1 cells were exposed to EXEL-0862 10 nM for 24 h before cell cycle analysis by flow cytometry.
mitochondrial damage through the generation of reactive oxygen species (ROS). We measured the levels of superoxide in EOL-1 cells cultured with escalating concentrations of EXEL-0862 for 16 h by labeling cells with the superoxide-sensitive dye dihydroethidium (DHE). An approximately threefold increase in the mean superoxide radical level was observed in EOL-1 cells after treatment with the potent superoxide dismutase inhibitor 2-Methoxyestradiol (2-ME). 19 In contrast, treatment with EXEL-0862 failed to increase superoxide levels in EOL-1 cells (Figure 4d ). These data suggest that ROS might not be involved in the antineoplastic activity of EXEL-0862.
EXEL-0862 induces downregulation of Mcl-1
We explored the effect of increasing EXEL-0862 concentrations (range, 2-100 nM) for 24 h on the expression of other apoptosisrelated proteins by Western blot. Immunoblots did not reveal any appreciable change in the expression of Bcl-2, Bax and Bcl-xL ( Figure 5 ). However, a prominent degradation of Mcl-1 was observed. Mcl-1 localizes to the mitochondrial as well as other intracellular membranes and has a relatively short halflife. 20 To characterize further the effect of EXEL-0862 on Mcl-1 downregulation, protein synthesis was blocked in EOL-1 cells by the addition of the translation inhibitor cycloheximide (CHX) and the levels of Mcl-1 were dynamically monitored at 5, 15, 30 and 60 min by Western blot in the presence or absence of EXEL-0862. In control cells, the level of Mcl-1 was low but remained stable over time. However, in cells cultured in the presence of EXEL-0862, the levels of Mcl-1 significantly declined over time and became nearly undetectable after 1 h, suggesting that EXEL-0862 accelerated Mcl-1 degradation (Figure 6a ). In aggregate, these data demonstrate that, to some extent, EXEL-0862-induced Mcl-1 downregulation occurs at the posttranslational level.
Proteasome activation is a key pathway for the regulation of the levels of certain intracellular proteins in mammalian cells. Accordingly, we tested the possibility that EXEL-0862-induced Mcl-1 downregulation may be due to proteasome activation. EOL-1 cells were exposed to EXEL-0862 in the presence or absence of the proteasome inhibitor MG-132 and Mcl-1 levels were evaluated by Western blot. Pharmacologic inhibition of proteasome function by MG-132 failed to abrogate the EXEL-0862-mediated decline of Mcl-1 indicating that downregulation of this protein is mediated by a proteasome-independent mechanism (Figure 6b) cleaved products. 21 The S-19 antibody strongly recognizes the pro-form Mcl-1 and the 28 kDa cleavage products, but not other type of cleavage products. 22 To further explore the mechanism of Mcl-1 degradation, we monitored the expression of Mcl-1 by 
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Western blot with the S-19 antibody after 3, 6, 16 and 24 h in the presence of EXEL-0862. As shown in Figure 6c , Mcl-1 levels significantly declined at 16 h after EXEL-0862 treatment. In parallel, the levels of the Mcl-1 128-350 cleaved product (p28) were found to be increased at this time point. These events temporally overlapped with caspase-3 activation and PARP cleavage (Figures 3c and 6c) . Since Mcl-1 is reported to be a substrate of caspase-3, 21 we hypothesized that Mcl-1 degradation was due to caspase-3 activation. To test this hypothesis, the broad-spectrum caspase inhibitor z-VAD.fmk was added to the culture in the absence or presence of EXEL-0862. Western blot analysis showed that z-VAD.fmk inhibited significantly the breakdown of the pro-form of Mcl-1 (p42) (Figure 6d) . Interestingly, treatment with the caspase-3 inhibitor z-DEVD-fmk, but not the caspase-2 inhibitor z-VDVAD-fmk, blocked the decline of the pro-form Mcl-1 induced by EXEL-0862 (Figure 6d) . Thus, inhibition of caspase-3 abrogates EXEL-0862-induced Mcl-1 degradation, suggesting that caspase-3 might be the main effector mediating this effect. When the EOL-1 were exposed to MEK inhibitor CI1040 for 24 h at concentrations up to 3.0 mM, neither the number of apoptotic cells increased nor the level of Mcl-1 declined (data not shown), suggesting that MEK inhibition alone is not sufficient to induce apoptosis and Mcl-1 cleavage in FIP1L1-PDGFR-a-expressing cells.
Discussion
Several chromosomal rearrangements encountered in hematologic malignancies involve protein tyrosine kinase genes. 23 The Bcr-Abl oncogene, encountered in patients with CML, not only constitutes a paradigmatic example of how constitutively active tyrosine kinases drive leukemogenesis, but also of how these molecular constructs are amenable to inhibition by small molecules. HES is characterized by persistent, unexplained hypereosinophilia leading to end-organ damage due to eosinophil degranulation of toxic mediators. 2 Until recently, HES has defied molecular characterization and therapy has been directed toward palliation of symptoms derived from organ involvement. The discovery of the constitutively active FIP1L1-PDGFR-a fusion kinase in a subset of patients with HES, that is sensitive to imatinib, has changed the therapeutic approach to patients with this disorder. 4 In the present study, we investigated the activity of the novel multitargeted TKI EXEL-0862 against the human FIP1L1-PDGFR-a-expressing cells to determine whether this compound might be a potential candidate for clinical development in patients with HES. We documented that 25, 26 results in subcellular relocation of these molecules to the nucleus where they activate a number of transcription factors. In addition, STAT3 can function as an oncogene protecting cells from apoptosis 24, 27 and Erk1/2 enhances the activity of anti-apoptotic Bcl-2 family members, such as Bcl-2 and Mcl-1. 28, 29 Collectively, our data suggested that EXEL-0862 decreased proliferation and induced apoptosis through ablation of STAT3 and Erk1/2 phosphorylation.
The clinical observation that some patients with HES exhibited a dramatic response to imatinib led to the discovery of the FIP1L1-PDGFR-a fusion gene. 4 This oncogene translates into a constitutively activated tyrosine kinase that is characteristically sensitive to low-dose imatinib. 4, 7 Notably, FIP1L1 is dispensable for the activation of PDGFR-a and disruption of the autoregulatory juxtamembrane domain of PDGFR-a is responsible for kinase activation and the transforming potential of FIP1L1-PDGFR-a. 30 The frequency of the FIP1L1-PDGFR-a transcript in HES has been reported as ranging from 0 to 56%, suggesting both referral and selection bias. 31 Despite the success of imatinib in the treatment of patients with HES harboring the oncogenic FIP1L1-PDGFR-a kinase, the development of imatinib resistance has been reported. 7 Together these observations suggest that single-agent TKI therapy might not be sufficient to achieve complete durable responses in all patients and that combination therapies with agents that either have enhanced potency or different mechanisms of action is warranted. It has been recently reported that nilotinib has equipotent in vitro activity against EOL-1 cells as compared with imatinib, 32 and that the multikinase inhibitor sorafenib inhibits the growth of BaF3 cells bearing FIP1L1-PDGFR-a at low nanomolar concentrations. 30 In addition, PKC412 has also shown activity against FIP1L1-PDGFR-a in vitro and in a murine model of FIP1L1-PDGFR-a-induced myeloproliferative disorder (MPD). 7 Whether nilotinib is active against T674I FIP1L1-PDGFR-a is, however, controversial. While Stover et al. reported that nilotinib is not active in T674I FIP1L1-PDGFR-a, 33 Bubnoff et al. reported that this compound inhibits BaF3 cells carrying T674I FIP1L1-PDGFR-a with an IC 50 of 376 nM, a concentration that can be clinically achievable.
34 PKC412 7 and sorafenib have also shown activity against the imatinib-resistant mutant T674I that is analogous to the imatinib-resistant T315I in Bcr-Abl, 9 which is notorious for conferring resistance to all TKIs currently available in the clinic. A reasonable strategy to prevent or circumvent resistance is the use of combinations of agents with synergistic non-cross-resistant compounds that would ideally include small-molecule TKIs acting on different structural motifs of the target protein.
This study not only demonstrates that EXEL-0862 promotes apoptosis of FIP1L1-PDGFR-a-expressing cells, but also highlights that EXEL-0862 may exert this effect through downregulation of the antiapoptotic protein Mcl-1. We demonstrated that exposure of EOL-1 cells to EXEL-0862 leads to alteration of mitochondrial membrane potential, release of cytochrome c and caspase-3 and -9 cleavage with release of their active fragments, which result in morphologic changes characteristic of apoptotic cell death. The mechanisms by which these events take place are not completely understood. Our data suggest that EXEL-0862 triggers apoptosis of FIP1LI-PDGFR-a-bearing cells through a ROS-independent mechanism of mitochondrial damage that leads to release of cytochrome c and caspase activation.
Because inhibition of protein synthesis by CHX in the presence of EXEL-0862 led to increased degradation of Mcl-1 in a time-and dose-dependent manner without affecting other members of the Bcl-2 family, we postulate that Mcl-1 downregulation is, at least in part, due to modifications at the posttranslational level. This is a distinctive feature of EXEL-0862 compared with cyclin-dependent kinase inhibitors, such as flavopiridol, which induces apoptosis through inhibition of Mcl-1 mRNA transcription. 35 It has been recently reported that hematopoietic 36, 37 and solid tumor cell lines 36 exposed to sorafenib display selective Mcl-1 downregulation in a mitogenactivated protein kinase (MEK)/Erk-independent manner. It is controversial whether sorafenib downregulates Mcl-1 at a posttranslational level, 36 similar to EXEL-0862, or else this is mediated through inhibition of Mcl-1 translation. 37 Interestingly, the effect of EXEL-0862 on EOL-1 cells with regard to Mcl-1 downregulation is reminiscent of that induced by MEK inhibitors. [38] [39] [40] Since EXEL-0862 exerts a potent inhibitory effect on the phosphorylation of Erk1/2, it is tempting to hypothesize that EXEL-0862-induced Mcl-1 downregulation is dependent on downregulation of the MEK/Erk pathway. Consistent with this latter possibility, it has been reported that inhibition of MEK1 modulates the expression of several Bcl-2 family members. 38, 39, 41 Given the potent inhibitory activity of EXEL-0862 on other tyrosine kinases such as VEGFR2, and FLT3, it is possible that interference with elements downstream from these targets may contribute to Mcl-1 downregulation. Since Mcl-1 appears to protect cells from proapoptotic stimuli that activate the mitochondrial apoptotic pathway, 20 it is possible that EXEL-0862-induced MEK/Erk1/2-mediated Mcl-1 downregulation may lower the apoptotic threshold and sensitize cells to other drugs that promote apoptosis through the mitochondrial pathway, such as adaphostin. 42 Noteworthy, inhibition of the proteasome system with MG-132 did not abolish Mcl-1 degradation, indicating that the latter occurs through a proteasome-independent pathway, whereas exposure to the pancaspase inhibitor z-VAD.fmk prevented 128-350 generated during EXEL-0862 treatment could contribute to the amplification loop of apoptosis in FIP1L1-PDGFR-a-expressing cells.
In summary, we have shown that the small-molecule kinase inhibitor EXEL-0862 is effective in vitro and ex vivo against FIP1L1-PDGFR-a fusion tyrosine kinase encountered in a subset of patients with HES. Moreover, caspase-3-mediated Mcl-1 downregulation appears to be responsible for the pro-apoptotic effects of EXEL-0862 on FIP1L1-PDGFR-a-expressing cells. EXEL-0862 could therefore be an effective therapy in malignancies bearing FIP1L1-PDGFR-a and other forms of activated PDGFR-a.
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